Zeitschrift für Arzneimittelentwicklung
Offener Zugang
ISSN: 2329-6631
ISSN: 2329-6631
Vishakha Saini, Sahil Dhiman, Avdesh Saini
Pharmacovigilance (PV) is the action of gathering, monitoring, investigating, analyzing, and evaluating pertinent data with the goal of lowering the frequency and severity of adverse effects. There is no doubt that pharmaceutical risk and risk-benefit analysis will continue to evolve in the future, but at the price of upheavals, disputes, and challenges to established institutions. It also shows that the patients are involved in the clinical trial for ensuring the safety of medicines. The Centre National de Pharmacovigilance et de Materiovigilance was created and supported by the Algerian Ministry of Health (MOH) in 1998. Due to the absence of long-term safety data as well as unanticipated interactions along with underlying clinical disorders and other medication regimens, rare side effects may not always be detected in clinical studies. In this review, the comparison of the pharmacovigilance between US, India and Europe show that the PV in the India show better activity for measuring the adverse effect due to the large number of populations.